$BCDA
BioCardia, Inc.

2020 Q1 Form 10-K Financial Statement

#000143774920007405 Filed on April 09, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2018 Q4 2018
Revenue $38.00K $100.0K $625.0K
YoY Change -82.41% 0.0% 30.48%
Cost Of Revenue $4.000K $120.0K $517.0K
YoY Change -96.23% -29.41% -25.07%
Gross Profit $34.00K -$10.00K $108.0K
YoY Change -69.09% -85.71% -151.18%
Gross Profit Margin 89.47% -10.0% 17.28%
Selling, General & Admin $1.857M $1.440M $5.757M
YoY Change 13.86% -14.79% -9.98%
% of Gross Profit 5461.76% 5330.56%
Research & Development $2.786M $2.210M $8.453M
YoY Change 28.62% 24.86% 45.77%
% of Gross Profit 8194.12% 7826.85%
Depreciation & Amortization $22.00K $20.00K $88.00K
YoY Change -4.35% 0.0% 12.82%
% of Gross Profit 64.71% 81.48%
Operating Expenses $4.643M $3.640M $14.21M
YoY Change 22.28% 5.51% 16.53%
Operating Profit -$4.609M -$3.650M -$14.10M
YoY Change 25.01% 3.69% 13.68%
Interest Expense $20.00K $20.00K
YoY Change 0.0% -50.0%
% of Operating Profit
Other Income/Expense, Net $15.00K $0.00 $115.0K
YoY Change -31.82% 18.56%
Pretax Income -$4.590M -$3.640M -$13.99M
YoY Change 25.07% 4.3% 13.65%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.594M -$3.640M -$13.99M
YoY Change 25.35% 4.3% 13.64%
Net Earnings / Revenue -12089.47% -3640.0% -2237.92%
Basic Earnings Per Share
Diluted Earnings Per Share -$672.0K -$844.5K -$3.284M
COMMON SHARES
Basic Shares Outstanding 6.848M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2018 Q4 2018
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.590M $5.360M $5.360M
YoY Change -8.8% -57.76% -57.76%
Cash & Equivalents $2.587M $5.358M $5.360M
Short-Term Investments
Other Short-Term Assets $450.0K $450.0K $450.0K
YoY Change 55.17% 32.35% 32.35%
Inventory $141.0K $140.0K
Prepaid Expenses $445.0K
Receivables $179.0K $274.0K $270.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $3.219M $6.218M $6.220M
YoY Change -8.76% -53.3% -53.3%
LONG-TERM ASSETS
Property, Plant & Equipment $164.0K $145.0K $150.0K
YoY Change -6.29% -14.2% -11.76%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $54.00K $54.00K $50.00K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $1.165M $199.0K $200.0K
YoY Change -28.48% -10.76% -9.09%
TOTAL ASSETS
Total Short-Term Assets $3.219M $6.218M $6.220M
Total Long-Term Assets $1.165M $199.0K $200.0K
Total Assets $4.384M $6.417M $6.420M
YoY Change -14.99% -52.6% -52.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.108M $743.0K $1.020M
YoY Change -2.72% -17.63% 13.33%
Accrued Expenses $99.00K $127.0K $1.530M
YoY Change -83.39% -72.69% 183.33%
Deferred Revenue $104.0K $112.0K
YoY Change -11.86% 83.61%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.510M $2.548M $2.550M
YoY Change 35.72% 9.26% 9.44%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.160M $80.00K $80.00K
YoY Change 13.73% 0.0% 0.0%
Total Long-Term Liabilities $1.160M $80.00K $80.00K
YoY Change 13.73% 0.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.510M $2.548M $2.550M
Total Long-Term Liabilities $1.160M $80.00K $80.00K
Total Liabilities $5.667M $2.625M $2.630M
YoY Change 30.61% 8.79% 9.13%
SHAREHOLDERS EQUITY
Retained Earnings -$105.7M -$86.36M
YoY Change 17.37% 19.2%
Common Stock $7.000K $5.000K
YoY Change -84.09% -86.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.283M $3.792M $3.790M
YoY Change
Total Liabilities & Shareholders Equity $4.384M $6.417M $6.420M
YoY Change -14.99% -52.6% -52.58%

Cashflow Statement

Concept 2020 Q1 2018 Q4 2018
OPERATING ACTIVITIES
Net Income -$4.594M -$3.640M -$13.99M
YoY Change 25.35% 4.3% 13.64%
Depreciation, Depletion And Amortization $22.00K $20.00K $88.00K
YoY Change -4.35% 0.0% 12.82%
Cash From Operating Activities -$2.993M -$3.250M -$11.07M
YoY Change 21.42% 28.97% 27.66%
INVESTING ACTIVITIES
Capital Expenditures $5.000K -$20.00K $66.00K
YoY Change -90.91% -33.33% -51.47%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$5.000K -$20.00K -$66.00K
YoY Change -90.91% -101.13% -51.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.790M 3.804M
YoY Change 3345.45% 2541.67%
NET CHANGE
Cash From Operating Activities -2.993M -3.250M -11.07M
Cash From Investing Activities -5.000K -20.00K -66.00K
Cash From Financing Activities 3.790M 3.804M
Net Change In Cash -2.998M 520.0K -7.331M
YoY Change 18.97% -181.25% -15.38%
FREE CASH FLOW
Cash From Operating Activities -$2.993M -$3.250M -$11.07M
Capital Expenditures $5.000K -$20.00K $66.00K
Free Cash Flow -$2.998M -$3.230M -$11.14M
YoY Change 18.97% 29.72% 26.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016 bcda Adjustments To Equity To Reflect The Impact Of Reverse Stock Split
AdjustmentsToEquityToReflectTheImpactOfReverseStockSplit
39000
CY2019 bcda Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
2139512
CY2019 bcda Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice
6.30
CY2018 bcda Adjustments To Equity To Reflect The Impact Of Reverse Stock Split
AdjustmentsToEquityToReflectTheImpactOfReverseStockSplit
39000
CY2017 bcda Adjustments To Equity To Reflect The Impact Of Reverse Stock Split
AdjustmentsToEquityToReflectTheImpactOfReverseStockSplit
39000
CY2019Q4 bcda Accrued Director Compensation Current
AccruedDirectorCompensationCurrent
648000
CY2018Q4 bcda Accrued Director Compensation Current
AccruedDirectorCompensationCurrent
277000
CY2019Q4 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
2561000
CY2018Q4 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
1805000
CY2019Q4 bcda Accrued Salaries And Employee Benefits Current
AccruedSalariesAndEmployeeBenefitsCurrent
652000
CY2018Q4 bcda Accrued Salaries And Employee Benefits Current
AccruedSalariesAndEmployeeBenefitsCurrent
368000
CY2019Q4 bcda Accured Clinical Trial Costs
AccuredClinicalTrialCosts
519000
CY2018Q4 bcda Accured Clinical Trial Costs
AccuredClinicalTrialCosts
276000
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-12-31
CY2019Q4 bcda Deferred Tax Assets Net Operating Loss And Tax Credit Carryforwards Noncurrent
DeferredTaxAssetsNetOperatingLossAndTaxCreditCarryforwardsNoncurrent
23809000
CY2018Q4 bcda Deferred Tax Assets Net Operating Loss And Tax Credit Carryforwards Noncurrent
DeferredTaxAssetsNetOperatingLossAndTaxCreditCarryforwardsNoncurrent
20698000
CY2019Q4 bcda Grant Liability Current
GrantLiabilityCurrent
630000
CY2018Q4 bcda Grant Liability Current
GrantLiabilityCurrent
645000
CY2019 bcda Increase Decrease In Current Operating Lease Liability
IncreaseDecreaseInCurrentOperatingLeaseLiability
88000
CY2018 bcda Increase Decrease In Current Operating Lease Liability
IncreaseDecreaseInCurrentOperatingLeaseLiability
CY2017 bcda Increase Decrease In Current Operating Lease Liability
IncreaseDecreaseInCurrentOperatingLeaseLiability
CY2019 bcda Increase Decrease In Non Current Operating Lease Liability
IncreaseDecreaseInNonCurrentOperatingLeaseLiability
-528000
CY2018 bcda Increase Decrease In Non Current Operating Lease Liability
IncreaseDecreaseInNonCurrentOperatingLeaseLiability
CY2017 bcda Increase Decrease In Non Current Operating Lease Liability
IncreaseDecreaseInNonCurrentOperatingLeaseLiability
CY2018 bcda Issuance Of Common Stock And Warrants Value
IssuanceOfCommonStockAndWarrantsValue
3800000
CY2019 bcda Issuance Of Common Stock And Warrants Value
IssuanceOfCommonStockAndWarrantsValue
9196000
CY2019 bcda Issuance Of Restricted Stock Units In Lieu Of Cash Bonus
IssuanceOfRestrictedStockUnitsInLieuOfCashBonus
165000
CY2018 bcda Issuance Of Restricted Stock Units In Lieu Of Cash Bonus
IssuanceOfRestrictedStockUnitsInLieuOfCashBonus
CY2017 bcda Issuance Of Restricted Stock Units In Lieu Of Cash Bonus
IssuanceOfRestrictedStockUnitsInLieuOfCashBonus
CY2019 bcda Operating Lease Interest Expense
OperatingLeaseInterestExpense
161000
CY2019 bcda Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
440000
CY2018 bcda Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
CY2017 bcda Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
CY2019 bcda Operating Lease Variable Lease Expense
OperatingLeaseVariableLeaseExpense
264000
CY2019Q4 bcda Prepaid Expense And Other Current Assets
PrepaidExpenseAndOtherCurrentAssets
642000
CY2018Q4 bcda Prepaid Expense And Other Current Assets
PrepaidExpenseAndOtherCurrentAssets
445000
CY2018Q4 bcda Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
3800000
CY2019 bcda Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
10452000
CY2018 bcda Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
4000000
CY2017 bcda Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
CY2019 bcda Proceeds From Issuance Of Convertible Notes And Warrants
ProceedsFromIssuanceOfConvertibleNotesAndWarrants
625000
CY2018 bcda Proceeds From Issuance Of Convertible Notes And Warrants
ProceedsFromIssuanceOfConvertibleNotesAndWarrants
CY2017 bcda Proceeds From Issuance Of Convertible Notes And Warrants
ProceedsFromIssuanceOfConvertibleNotesAndWarrants
CY2019 bcda Standard Product Warranty Term
StandardProductWarrantyTerm
P2Y
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0000925741
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6848355
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2722000
CY2018 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
200000
CY2019 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1259000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2722000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2774000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2707000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2000
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
9000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3294253
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
934541
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
479010
CY2019Q4 us-gaap Assets
Assets
7678000
CY2018Q4 us-gaap Assets
Assets
6417000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
6378000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
6218000
CY2019Q2 dei Entity Public Float
EntityPublicFloat
23226531
CY2019 dei Entity Registrant Name
EntityRegistrantName
BioCardia, Inc.
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
CY2019 dei Trading Symbol
TradingSymbol
bcda
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
914000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
743000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
147000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
274000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
127000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
957000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
845000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
103433000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
90148000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2707000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2774000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5585000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5358000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12689000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21352000
CY2019 us-gaap Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
227000
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-7331000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-8663000
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.75
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.75
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.36
CY2018Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
0.5
CY2018Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
296296
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
296296
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2435808
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
592592
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6825183
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4845697
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6825183
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4845697
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"><tr><td style="vertical-align:top;width:6.7%;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></div> </td> <td style="vertical-align:top;width:5%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">(e)</div></div></div> </td> <td style="vertical-align:top;width:88.3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentration of Credit Risk</div></div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:61.2pt;margin-right:7.2pt;margin-top:0pt;text-align:justify;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company maintains its cash at financial institutions, which at times, exceed federally insured limits. At <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019, </div>the Company&#x2019;s cash was held by <div style="display: inline; font-style: italic; font: inherit;">one</div> financial institution and the amount on deposit was in excess of FDIC insurance limits. The Company has <div style="display: inline; font-style: italic; font: inherit;">not</div> recognized any losses from credit risks on such accounts since inception. The Company believes it is <div style="display: inline; font-style: italic; font: inherit;">not</div> exposed to significant credit risk on cash and cash equivalents.</div></div></div></div></div></div></div>
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
102000
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
112000
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
358000
CY2018 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
517000
CY2017 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
690000
CY2019 us-gaap Costs And Expenses
CostsAndExpenses
14923000
CY2018 us-gaap Costs And Expenses
CostsAndExpenses
14727000
CY2017 us-gaap Costs And Expenses
CostsAndExpenses
12884000
CY2017Q4 us-gaap Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
76000
CY2019 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
633000
CY2018 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
CY2017 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
CY2019Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
77000
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
691000
CY2018Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
25107000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
21831000
CY2019Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
297000
CY2018Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
276000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
11000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
12000
CY2019Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
98000
CY2018Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
113000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
148000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
84000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
744000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
648000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
25107000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
21831000
CY2018Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2019Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
25000
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
26000
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2019 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.75
CY2019 us-gaap Depreciation
Depreciation
111000
CY2018 us-gaap Depreciation
Depreciation
88000
CY2017 us-gaap Depreciation
Depreciation
78000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
111000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
88000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
78000
CY2019 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
52000
CY2018 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
CY2017 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-455000
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.61
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.28
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.90
CY2019 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-521000
CY2018 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
CY2017 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3277000
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3166000
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-2965000
CY2019 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
CY2018 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
8172000
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3089000
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2937000
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-4185000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
446000
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
440000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
344000
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
5000
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
22000
CY2017 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
7000
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-414000
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
CY2018Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
39000
CY2019 us-gaap Inventory Write Down
InventoryWriteDown
1000
CY2018 us-gaap Inventory Write Down
InventoryWriteDown
CY2017 us-gaap Inventory Write Down
InventoryWriteDown
CY2019 us-gaap Lease Cost
LeaseCost
865000
CY2017 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1238000
CY2019 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
225000
CY2018 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
236000
CY2017 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
135000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
171000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
119000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
377000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-127000
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
179000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
21000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
922000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
240000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
415000
CY2019 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
CY2018 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-4000
CY2017 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
25000
CY2019 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
691000
CY2018 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-65000
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
96000
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-136000
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-49000
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
56000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
198000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
104000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-16000
CY2019 us-gaap Interest Expense
InterestExpense
112000
CY2018 us-gaap Interest Expense
InterestExpense
CY2017 us-gaap Interest Expense
InterestExpense
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4000
CY2018Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
23000
CY2019Q4 us-gaap Inventory Net
InventoryNet
4000
CY2018Q4 us-gaap Inventory Net
InventoryNet
141000
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
CY2018Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
79000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1142000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
528000
CY2018Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
614000
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1279000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
630000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
649000
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
137000
CY2019Q4 us-gaap Liabilities
Liabilities
5308000
CY2018Q4 us-gaap Liabilities
Liabilities
2625000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7678000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6417000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4003000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2548000
CY2019 us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="vertical-align:top;width:5%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">(</div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">14</div></div><div style="display: inline; font-weight: bold;">)</div></div> </td> <td style="vertical-align:top;width:95%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Contingencies and Uncertainties</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 34.2pt; text-align: justify;"><div style="display: inline; font-style: italic;">Contingencies</div> - The Company <div style="display: inline; font-style: italic; font: inherit;"> may </div>be subject to various claims, complaints, and legal actions that arise from time to time in the normal course of business. Management is <div style="display: inline; font-style: italic; font: inherit;">not</div> aware of any current legal or administrative proceedings that are likely to have an adverse effect on the Company&#x2019;s business, financial position, results of operations, or cash flows.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 34.2pt; text-align: justify;"><div style="display: inline; font-style: italic;">Uncertainties</div> - Prior to <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019, </div>a new strain of coronavirus originating in Wuhan, China (the &#x201c;COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> outbreak&#x201d;) affected the People&#x2019;s Republic of China, and the unknown risks to the international community began to escalate as the virus spread globally beyond its point of origin. Disclosures concerning the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> outbreak by the government of the People&#x2019;s Republic of China were <div style="display: inline; font-style: italic; font: inherit;">not</div> extensive prior to <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 34.2pt; text-align: justify;">In <div style="display: inline; font-style: italic; font: inherit;"> March 2020, </div>the World Health Organization declared the outbreak of COVID-<div style="display: inline; font-style: italic; font: inherit;">19,</div> a novel strain of Coronavirus, a global pandemic. This outbreak is causing major disruptions to businesses and financial markets worldwide as the virus spreads. If the outbreak continues to spread, it <div style="display: inline; font-style: italic; font: inherit;"> may </div>affect the Company&#x2019;s operations and those of <div style="display: inline; font-style: italic; font: inherit;">third</div> parties on which the Company relies, including causing disruptions in the supply of the Company&#x2019;s product candidates and the conduct of current and planned preclinical and clinical studies. BioCardia <div style="display: inline; font-style: italic; font: inherit;"> may </div>need to limit operations and <div style="display: inline; font-style: italic; font: inherit;"> may </div>experience limitations in employee resources. There are risks that the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> outbreak <div style="display: inline; font-style: italic; font: inherit;"> may </div>be more difficult to contain if the outbreak reaches a larger population or broader geography, in which case the risks described herein could be elevated significantly. The extent to which the coronavirus impacts the Company&#x2019;s results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which <div style="display: inline; font-style: italic; font: inherit;"> may </div>emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 34.2pt; text-align: justify;">Additionally, while the potential economic impact brought by, and the duration of, a coronavirus pandemic is difficult to assess or predict, the impact of the coronavirus on the global financial markets <div style="display: inline; font-style: italic; font: inherit;"> may </div>reduce the Company&#x2019;s ability to access capital, which could negatively impact the Company&#x2019;s short-term and long-term liquidity, and the Company&#x2019;s ability to complete its preclinical and clinical studies on a timely basis, or at all. The ultimate impact of coronavirus is highly uncertain and subject to change. The Company does <div style="display: inline; font-style: italic; font: inherit;">not</div> yet know the full extent of potential delays or impacts on its business, financing, preclinical and clinical trial activities or the global economy as a whole. However, these effects could have a material, adverse impact on the Company&#x2019;s liquidity, capital resources, operations and business and those of the <div style="display: inline; font-style: italic; font: inherit;">third</div> parties on which BioCardia relies.</div></div>
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9818000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3804000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
144000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-146000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-66000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-136000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9445000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11069000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8671000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-14709000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-13987000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-12308000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-496000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
115000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
97000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-14213000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-14102000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-12405000
CY2018 us-gaap Operating Lease Expense
OperatingLeaseExpense
601000
CY2017 us-gaap Operating Lease Expense
OperatingLeaseExpense
601000
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
601000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
612000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1065000
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1205
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1891000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
612000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
649000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
630000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
54000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
54000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
CY2019 us-gaap Other Operating Income
OtherOperatingIncome
87000
CY2018 us-gaap Other Operating Income
OtherOperatingIncome
118000
CY2017 us-gaap Other Operating Income
OtherOperatingIncome
95000
CY2019 us-gaap Paid In Kind Interest
PaidInKindInterest
112000
CY2018 us-gaap Paid In Kind Interest
PaidInKindInterest
CY2017 us-gaap Paid In Kind Interest
PaidInKindInterest
CY2018Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
200000
CY2019 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1259000
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
200000
CY2017 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
146000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
66000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
136000
CY2019 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
CY2018 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
CY2017 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
1800000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
CY2018 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
CY2017 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
1800000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
144000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1138000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
990000
CY2019 us-gaap Property Plant And Equipment Impairment
PropertyPlantAndEquipmentImpairment
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"><tr><td style="vertical-align:top;width:6.7%;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></div> </td> <td style="vertical-align:top;width:5%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">(j)</div></div></div> </td> <td style="vertical-align:top;width:88.3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Long-lived Assets</div></div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:61.2pt;margin-right:7.2pt;margin-top:0pt;text-align:justify;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:61.2pt;margin-right:7.2pt;margin-top:0pt;text-align:justify;"><div style="display: inline; font-style: italic;">Impairment assessment of long</div><div style="display: inline; font-style: italic;">-</div><div style="display: inline; font-style: italic;">lived assets</div> - The carrying value of long-lived assets, including property and equipment and operating lease right-of-use assets, is reviewed for impairment whenever events or changes in circumstances indicate that the asset <div style="display: inline; font-style: italic; font: inherit;"> may </div><div style="display: inline; font-style: italic; font: inherit;">not</div> be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. Through <div style="display: inline; font-style: italic; font: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2019,</div> there have been <div style="display: inline; font-style: italic; font: inherit;">no</div> such impairment losses.</div></div></div></div></div></div></div>
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
181000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
145000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8562000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8453000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5799000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
41868
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
515036
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
254785
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101070000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-86361000
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
710000
CY2018 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
625000
CY2017 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
479000
CY2019Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
691000
CY2019Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y210D
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1505000
CY2018 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
CY2017 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
CY2018Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
6.75
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
144000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
20582000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
11125000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
3792000
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6003000
CY2018 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5757000
CY2017 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6395000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
2722000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
2774000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
2707000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
428793
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
23.62
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
400000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
2370000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.87
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
15.48
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
52.20
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
608547
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
821464
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
25.20
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.99
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
26.86
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.28
CY2019Q4 us-gaap Share Price
SharePrice
3.68
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y219D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y292D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y219D
CY2018Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
0
CY2019Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
0
CY2018Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
592592
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
CY2019 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1204000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
891000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
725000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1046000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
155000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
166000
CY2019Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
753000
CY2018Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
636000
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"><tr><td style="vertical-align:top;width:6.7%;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></div> </td> <td style="vertical-align:top;width:5%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">(c)</div></div></div> </td> <td style="vertical-align:top;width:88.3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:61.2pt;margin-right:7.2pt;margin-top:0pt;text-align:justify;">The preparation of the financial statements in accordance with U.S. GAAP requires Company management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include the useful lives of property and equipment, right-of-use assets and related liabilities, allowances for doubtful accounts and sales returns; inventory valuation, derivative instruments, clinical accruals, and share-based compensation.</div></div></div></div></div></div></div>
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3200000
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3200000
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5644328
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4264178
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4240060

Files In Submission

Name View Source Status
0001437749-20-007405-index-headers.html Edgar Link pending
0001437749-20-007405-index.html Edgar Link pending
0001437749-20-007405.txt Edgar Link pending
0001437749-20-007405-xbrl.zip Edgar Link pending
bcda-20191231.xml Edgar Link completed
bcda-20191231.xsd Edgar Link pending
bcda-20191231_cal.xml Edgar Link unprocessable
bcda-20191231_def.xml Edgar Link unprocessable
bcda-20191231_lab.xml Edgar Link unprocessable
bcda-20191231_pre.xml Edgar Link unprocessable
bcda20191231_10k.htm Edgar Link pending
ex_166908.htm Edgar Link pending
ex_166909.htm Edgar Link pending
ex_166911.htm Edgar Link pending
ex_166912.htm Edgar Link pending
ex_166913.htm Edgar Link pending
ex_166914.htm Edgar Link pending
ex_179353.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sig.jpg Edgar Link pending